[Comparative evaluation of the effectiveness of mono- and polychemotherapy programs in patients with multiple myeloma].
作者信息
Abdulkadyrov K M, Bessmel'tsev S S
出版信息
Klin Med (Mosk). 1992 Sep-Oct;70(9-10):57-60.
PMID:1474818
Abstract
摘要
相似文献
1
[Comparative evaluation of the effectiveness of mono- and polychemotherapy programs in patients with multiple myeloma].
Klin Med (Mosk). 1992 Sep-Oct;70(9-10):57-60.
2
Bortezomib data show improved survival in patients with relapsed multiple myeloma.硼替佐米的数据显示复发型多发性骨髓瘤患者的生存率有所提高。
Oncology (Williston Park). 2004 Aug;18(9):1199, 1201.
3
[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].沙利度胺治疗难治性多发性骨髓瘤：荷兰对72例患者的研究：45%有抗肿瘤效果
Ned Tijdschr Geneeskd. 2002 Aug 3;146(31):1445-8.
4
[Polychemotherapy versus melphalan-prednisone in multiple myeloma].
G Clin Med. 1986 Dec;67(5-6):291-6.
5
Polychemotherapy (COMP) treatment in myeloma patients. A preliminary report.骨髓瘤患者的多药化疗（COMP）治疗。初步报告。
Haematologica. 1983 May-Jun;68(3):381-91.
6
Treatment of multiple myeloma and arterial thrombosis.多发性骨髓瘤与动脉血栓形成的治疗。
Ann Hematol. 2010 Apr;89(4):419-20. doi: 10.1007/s00277-009-0803-x. Epub 2009 Aug 18.
7
Bortezomib therapy following first relapse.首次复发后的硼替佐米治疗。
Oncology (Williston Park). 2005 Jan;19(1):23-6.
8
Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
Haematologica. 2003 Dec;88(12):1432-3.
9
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.来那度胺（瑞复美）联合环磷酰胺和地塞米松（RCD）方案，对于骨髓瘤患者而言是一种有效且耐受性良好的治疗方案。
Br J Haematol. 2007 May;137(3):268-9. doi: 10.1111/j.1365-2141.2007.06538.x.
10
[The efficacy of polychemotherapy programs in treating multiple myeloma patients].[多药化疗方案治疗多发性骨髓瘤患者的疗效]
Ter Arkh. 1998;70(7):46-9.
Zotero 插件